Vaccination Against Canine Cancer Study (VACCS)
VACCS is a randomized, placebo-controlled study protocol testing a cancer preventative vaccine against frameshift neoantigens in companion dogs, described as the largest interventional cancer clinical trial conducted in companion dogs to date. Its primary endpoint is the cumulative incidence of malignant neoplasia of any type at the end of the study period, alongside safety and immunogenicity, with secondary endpoints of specific tumor incidence, survival after neoplasia diagnosis and all-cause mortality. No results are reported in the protocol paper.
Record
| Design | randomized controlled trial |
|---|---|
| Status | ongoing |
| Setting | client owned |
| Intervention | Cancer preventative vaccine targeting frameshift neoantigens conserved across multiple species and tumor histologies |
| Intervention class | vaccine |
| Comparator | placebo |
| Population note | Described as the largest interventional cancer clinical trial conducted in companion dogs to date; enrollment number not stated in the abstract |
| Other | Companion dogs |
| Primary outcome | Cumulative incidence (CI) of dogs developing malignant neoplasia of any type at the end of the study period, in addition to safety and immunogenicity; secondary endpoints are changes in incidence of specific tumor types, survival times following neoplasia diagnosis, and all-cause mortality |
| Tags | vaccine, cancer-prevention, companion-dogs, ongoing, neoantigen |
Notes: Protocol paper. The design wording 'randomized, placebo-controlled' comes from the paper title (Design of a randomized, placebo-controlled study evaluating efficacy and safety of a cancer preventative vaccine in dogs), which the abstract body does not restate; the abstract gives no age range, enrollment number, dose schedule, lead institution, sponsor or registration id. Included under the registry's cancer-prevention criterion.
Sources and verbatim quotes
Design of a randomized, placebo-controlled study evaluating efficacy and safety of a cancer preventative vaccine in dogs. (2024) PMID 38056066 (design)
Identification and vaccination against frameshift neoantigens conserved across multiple species and tumor histologies is a potential cancer preventative strategy currently being investigated.
Companion dogs spontaneously develop cancers at a similar incidence to those in people and are a complementary comparative patient population for the development of novel anti-cancer therapeutics.
Here we describe the study protocol for the Vaccination Against Canine Cancer Study (VACCS), the largest interventional cancer clinical trial conducted in companion dogs to date.
In addition to safety and immunogenicity, the primary endpoint of VACCS is the cumulative incidence (CI) of dogs developing malignant neoplasia of any type at the end of the study period.
Secondary endpoints include changes in incidence of specific tumor types, survival times following neoplasia diagnosis, and all-cause mortality.
Reproduce: canine_trial_search(trial_id="vaccs-cancer-preventative-vaccine") in dog-geroscience-mcp; dataset canine-trial-registry.